Yalcintepe, SinemGurkan, HakanKorkmaz, Fatma NurDemir, SelmaAtli, EnginEker, DamlaGuler, Hazal Sezginer2024-06-122024-06-1220212203-5826https://doi.org/10.15586/jkcvhl.v8i1.171https://hdl.handle.net/20.500.14551/23022The aim of this study was to evaluate germline variant frequencies of pheochromocytoma and paraganglioma targeted susceptibility genes with next-generation sequencing method. Germline DNA from 75 cases were evaluated with targeted next-generation sequencing on an Illumina NextSeq550 instrument. KIF1B. RET, SDHB, SDHD, TMEM127, and VHL genes were included in the study, and Sanger sequencing was used for verifying the variants. The pathogenic/likely pathogenic variants were in the VHL, RET, SDHB, and SDHD genes, and the diagnosis rate was 24% in this study. Three different novel pathogenic variants were determined in five cases. This is the first study from Turkey, evaluating germline susceptibility genes of pheochromocytoma and paraganglioma with a detection rate of 24% and three novel variants. All patients with pheochromocytoma and paraganglioma need clinical genetic testing with expanded targeted gene panels for higher diagnosis rates.en10.15586/jkcvhl.v8i1.171info:eu-repo/semantics/openAccessParagangliomaPheochromocytomaTargeted SequencingSusceptibility GenesGuidelinesGeneticsOutcomesArticle811924N/AWOS:00075242400000333777662